Small-Cap REIT ETF ...
Health Care: Drugs
NewLink Genetics Corp (NLNK: NASDAQ)
$16.68 0.40 | 2.46%
05/17/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | |||
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 20.25M | 39.49M | ||
| Receivables | 738.00K | 399.00K | ||
| Inventories | 0.00 | 0.00 | ||
| Other Current Assets | 907.00K | 0.00 | ||
| Total Current Assets | 23.39M | 42.79M | ||
| Property, Plant & Equipment, Gross | 9.02M | 8.50M | ||
| Accumulated Depreciation & Depletion | 2.98M | 2.91M | ||
| Property, Plant & Equipment, Net | 6.04M | 5.59M | ||
| Intangibles | 0.00 | 0.00 | ||
| Other Non-Current Assets | 0.00 | 0.00 | ||
| Total Non-Current Assets | 6.04M | 5.59M | ||
| Liabilities & Shareholder Equity | ||||
| Total Assets | 29.43M | 48.38M | ||
| Accounts Payable | 972.00K | 1.67M | ||
| Short Term Debt | 204.00K | 214.00K | ||
| Other Current Liabilities | 0.00 | 0.00 | ||
| Total Current Liabilities | 2.92M | 10.66M | ||
| Long Term Debt | 1.14M | 848.00K | ||
| Deferred Income Taxes | 0.00 | 0.00 | ||
| Other Non-Current Liabilities | 1.40M | 0.00 | ||
| Minority Interest | 0.00 | -1.00K | ||
| Total Non-Current Liabilities | 8.58M | 942.00K | ||
| Total Liabilities | 11.50M | 11.61M | ||
| Preferred Stock Equity | 0.00 | 0.00 | ||
| Common Stock Equity | 17.93M | 36.77M | ||
| Common Par | 210.00K | 206.00K | ||
| Additional Paid In Capital | 122.51M | 118.04M | ||
| Cumulative Translation Adjustment | 0.00 | 0.00 | ||
| Retained Earnings | -104.80M | -81.48M | ||
| Treasury Stock | 0.00 | 0.00 | ||
| Other Equity Adjustments | 0.00 | 0.00 | ||
| Total Capitalization | 19.07M | 37.62M | ||
| Total Equity | 17.93M | 36.77M | ||
| Total Liabilities & Stock Equity | 29.43M | 48.38M | ||
| Total Common Shares Outstanding | 20.99M | 20.59M | ||
| Preferred Shares | 0.00 | 0.00 | ||
| Treasury Shares | 0.00 | 0.00 | ||
| Basic Weighted Shares Outstanding | 20.78M | 6.06M | ||
| Diluted Weighted Shares Outstanding | 20.78M | 6.06M | ||
| Number of Employees | 94 | 77 | ||
| Number of Part-Time Employees | 0 | 0 | ||
Portfolios with NLNK
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
Latest NLNK Headlines from TheStreet
- 3 Biotech Stocks Spiking With Big Volume 05.13.13 | 02:05 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 5 Stocks With Big Insider Buying 02.06.13 | 12:02 pm
- Top Insider Trades: FB NLNK GD NOW 02.06.13 | 09:02 am
- Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data 09.25.12 | 08:09 am
- NewLink Announces An Investigator Initiated Phase 2 Study Of Sipuleucel-T Plus Indoximod In The Treatment Of Certain Men With Advanced Prostate Cancer 09.21.12 | 08:09 am
- NewLink CEO To Participate In Panel Entitled "Innovation In Immunotherapy And Vaccines" 09.20.12 | 08:09 am
- NewLink Genetics Corporation Reports Second Quarter 2012 Financial Results 08.14.12 | 08:08 am
- Pharma IPOs Are Good Medicine 07.23.12 | 07:07 am
- 7 Stocks Ripping Higher on Huge Volume 06.11.12 | 01:06 pm
Press Releases for NLNK
- NewLink Genetics To Present At The Needham And Company 12th Annual Healthcare Conference - PR Newswire 04.25.13 | 07:04 am
- NewLink Genetics Presents Preclinical Data On New IDO Pathway Inhibitor, NLG919, At AACR 2013 Annual Meeting - PR Newswire 04.08.13 | 07:04 am
- NewLink Genetics Presents Preclinical Data On NLG919, A New Drug Candidate From A Novel Class Of IDO Pathway Inhibitors For The Treatment Of Cancer - PR Newswire 04.04.13 | 07:04 am
- NewLink Genetics Initiates Phase 2 Trial Of IDO Pathway Inhibitor, Indoximod, For The Treatment Of Metastatic Breast Cancer - PR Newswire 04.02.13 | 07:04 am
- NewLink Genetics Announces Timing Of Fourth Quarter And Year-End 2012 Financial Results Conference Call - PR Newswire 02.25.13 | 11:02 am
- NewLink Genetics Corporation Announces Exercise Of Underwriters' Option And Closing Of Public Offering Of Common Stock - PR Newswire 02.04.13 | 09:02 am
- NewLink Genetics Corporation Announces Pricing Of Public Offering Of Common Stock - PR Newswire 01.30.13 | 09:01 am
- NewLink Genetics Corporation Announces Proposed Public Offering Of Common Stock - PR Newswire 01.29.13 | 04:01 pm
- NewLink Genetics Appoints Mr. Brian Wiley As Vice President Of Business Development - PR Newswire 01.03.13 | 07:01 am
- Clinical Data From NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published In Journal Of Immunotherapy - PR Newswire 12.13.12 | 07:12 am
Partner Headlines for NLNK
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- NewLink Genetics DROPS 11% and 4 Stock Analyses Making Waves - Wall St. Cheat Sheet 07.18.12 | 12:07 pm
- These Are Four of the Hottest Biotechs in the Market Right Now - Benzinga 07.05.12 | 01:07 pm
- Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel ... - GuruFocus 06.30.12 | 11:06 am
- Zumiez Lifted Among These Equity Analyst Insights Today - Wall St. Cheat Sheet 06.19.12 | 08:06 am
- Active Stock Alerts: Edwards Lifesciences, Pandora Media, NewLink Genetics, VMware June 6th - Wall St. Cheat Sheet 06.06.12 | 11:06 am
- New Share Price Targets to Evaluate Now - Wall St. Cheat Sheet 06.06.12 | 04:06 am
- Analysts Unveil These New Share Price Targets Tuesday - Wall St. Cheat Sheet 05.29.12 | 03:05 am
- Stock Insights: Costco Wholesale, Human Genome, NewLink Genetics, VeriFone,General Mills May 25th - Wall St. Cheat Sheet 05.25.12 | 10:05 am
- Must Know Share Price Targets That Changed Today - Wall St. Cheat Sheet 05.25.12 | 04:05 am
